Lino Biotech

Startup

Lino Biotech AG, based in Adliswil, Switzerland, is a pioneering company specializing in focal molography, a groundbreaking label-free biosensor platform that enables real-time analysis of biomolecular interactions in living cells and complex biological samples. Founded in March 2020, the company emerged from nearly eight years of scientific research at Roche and ETH Zurich. Lino Biotech aims to establish itself as a leader in life sciences, initially focusing on the drug development market.

The company’s first commercial instrument utilizes focal molography to revolutionize the measurement of biological interactions. This innovative approach provides a direct and undisturbed view of molecular dynamics in their natural state, eliminating the need for labels and overcoming traditional research limitations such as signal disturbance and non-specific binding. It enables real-time observation and quantification of biological processes, paving the way for more accurate, efficient, and straightforward studies in molecular interaction research.

Lino Biotech is particularly focused on several key areas:

• Target Identification: Understanding protein-protein interactions (PPIs) is essential for identifying potential drug targets, especially with membrane receptors like GPCRs and immune receptors for cell and gene therapy.
• Binder Development: The company aims to identify promising binders in the antibody development pipeline, concentrating on antibodies, antibody-drug conjugates, and DNA-based binders (aptamers).
• Hit Validation: Lino Biotech measures PPIs to validate initial hits from screening processes, ensuring their efficacy and relevance to therapeutic goals, with a focus on DNA-encoded libraries (DEL), peptides, DNA/RNA, and small fragments.

Through its advanced technology, Lino Biotech is transforming biological research, heralding a new era of precision in drug development and diagnostics, and positioning itself for rapid growth in the global life sciences market.

website